PETVIVO HOLDINGS, INC. TO EXHIBIT AT VETERINARY MEETING AND EXPO CONFERENCE IN ORLANDO, FLORIDA
January 10 2022 - 6:45AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets is pleased to announce
today it will be exhibiting at the Veterinary Meeting & Expo
Conference from January 15th to January 19th, 2022 at the Orange
County Convention Center in Orlando, FL.
The Company’s management is excited to meet with
many of the 7,500+ participants to introduce its lead product,
Spryng™ with OsteoCushion™ Technology, a veterinary medical device
injection of sterilized, naturally-derived hydrogel microparticles
that are wet, slippery and spongy used in the treatment of lameness
and other joint related afflictions, such as osteoarthritis. VMX is
the largest veterinary conference in the United States and plays
host to many of the top industry professionals.
“We are looking forward to networking with
leaders in the industry and develop relationships that will help
drive forward our innovative veterinary medical device for the
treatment of osteoarthritis, Spryng,” said John Lai, Chief
Executive Officer of PetVivo Holdings, Inc.
For more information about PetVivo Holdings,
Inc. please contact info1@petvivo.com or visit
https://petvivo.com/
Conference Details:
Veterinary Meeting & Expo (VMX)
Conference
Booth #: 3812
Dates:
Sunday, January 16, 2022 9:00am – 6:30pm
Monday, January 17, 2022 9:00am – 5:30pm
Tuesday, January 18, 2022 9:00am – 5:30pm
Wednesday, January 19, 2022 9:00am – 2:00pm
Location: South Concourse of the Orange County
Convention Center
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an
emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of twenty-one
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG, a
veterinarian-administered, intraarticular injection for the
treatment of lameness and other joint related afflictions,
including osteoarthritis, in dogs and horses, is scheduled for
expanded commercial sale in the fourth quarter of this year.
CONTACT:
John Lai, CEOPetVivo Holdings, Inc.Email:
info1@petvivo.com(952) 405-6216
Forward-Looking commercial
Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements,
including the potential listing of the Company’s common stock on
Nasdaq, are based on information currently available the Company
and its current plans or expectations and are subject to a number
of uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2021 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From Apr 2024 to May 2024
PetVivo (NASDAQ:PETVW)
Historical Stock Chart
From May 2023 to May 2024